Clinical Trial

HEPLISAV-B Exposure in Pregnant Women and Their Offspring

Study Description

DV2-HBV-27: Observational Pregnancy Registry

Purpose of the study is to evaluate pregnancy outcomes among women who received a dose of HEPLISAV-B within 28 days prior to conception or at any time during pregnancy

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - HEPLISAV-B

This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.

Additional Information

Official Study Title

HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring

Clinical Trial ID

NCT03664648

ParticipAid ID

dBBrNd